All In Biotech

Drug Trial Radar · NCT01882621

Monosialoganglioside(GM1) Preventing Neurotoxicity Induced by Cisplatin Contained Chemotherapy in NSCLC Patients

A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial of Monosialoganglioside(GM1) Preventing Neurotoxicity Induced by First-line Chemotherapy Contained Cisplatin in Non-small Cell Lung Cancer Patients.

Last checked: Nov 19, 2026Latest source record: Jun 1, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

300

Planned (sponsor's estimate)

Start

Oct 2013

Primary completion

Aug 2016

Study completion Aug 2016

Sponsor

Lead sponsor
Sun Yat-sen UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Southern Medical University, China
First posted
Jun 20, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Single group
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluate the efficacy and safety of Monosialoganglioside(GM1) to prevent the neurotoxicity induced by cisplatin

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • Monosialoganglioside(GM1)Drug

    80mg,ivdrip (in the vein) on day 0 - day 3 of each 21 day cycle. Number of Cycles: 4-6 cycles.

  • normal salineDrug

    80mg,ivdrip(in the vein) on day 0-3 of each 21 day cycle. Number of Cycles: 4-6 cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. incidence rate of neurotoxicity adverse eventsTime frame: up to 19 weeks after cisplatin chemotherapy

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-Sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.